P3 Health Partners Inc Dossier - Source-backed chat

P3 Health Partners Inc

PIIINASDAQ

SectorHealth Care

IndustryHealth Care Providers & Services

Beta (adjusted)1.44

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.27Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $1.3B

Enterprise Value $1.4B

Shares Outstanding 203.8M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

P3 Health Partners (PIII) has demonstrated a significant operational turnaround in Q1 2026, swinging to a net income of $3.0 million and delivering $25.8 million in Adjusted EBITDA. This improvement was driven by contract restructuring, network concentration, and a 15% increase in Medicare Advantage funding rates. However, the company continues to face substantial liquidity constraints, high leverage, and historical going-concern warnings. While the debt-to-preferred-equity exchange has shored up the balance sheet, a 'Hold' recommendation is maintained until the sustainability of these improved margins is proven over multiple quarters.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$14.00

Mean target$14.00

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

Medical cost trends spike or at-risk membership declines more rapidly than expected, eroding the Q1 margin gains. The company fails to meet its FY 2026 EBITDA guidance, leading to renewed liquidity pressure and covenant compliance issues.

Base CaseCentral scenario

$11.5050%

P3 Health Partners executes within its revised FY 2026 guidance, delivering revenues between $1.50 billion and $1.65 billion and Adjusted EBITDA of approximately $40 million (the midpoint of guidance). Liquidity stabilizes but leverage remains a watch item.

Bull CaseUpside scenario

$14.0030%

The operational turnaround accelerates with sustained medical margin expansion. The company successfully achieves the high end of its FY 2026 Adjusted EBITDA guidance ($60 million) and transitions to consistent positive free cash flow, eliminating going-concern risks.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Q1 2026 financial turnaround with positive net income of $3.0 million and $25.8 million in Adjusted EBITDA.
Successful execution of contract restructuring and network concentration, leading to a 14% increase in per-member revenue.
Improved capital structure following a debt exchange that converted significant debt obligations into preferred equity.

Key Investment Risks

Historically severe liquidity constraints and persistent going-concern doubts highlighted in the 2025 Form 10-K.
High reliance on a concentrated payer base, with four health plans historically generating approximately 75% of revenue.
Risk of medical cost trend volatility and regulatory changes in Medicare Advantage payment models.

Thesis Invalidation Triggers

Adjusted EBITDA falling below the lower bound of FY 2026 guidance ($20 million).
A material decline in cash reserves or failure to maintain compliance with debt covenants.
Inability to sustain the improved medical margin of $231 per-member per-month achieved in Q1 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.